Management of prostate-specific antigen relapse in prostate cancer: a European Consensus.
about
Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancerSalvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges.XPA-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrence.Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.Saudi Oncology Society clinical management guidelines for prostate cancer.Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trialsAssessment of a new point-of-care system for detection of prostate specific antigenAdvanced prostate cancer treatment guidelines: European perspective.Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National DatabaseEvaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer.Using prostate-specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer.Approach to primary care follow-up of patients with prostate cancer.Predictive factors for biochemical recurrence in radical prostatectomy patientsThe loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients.Oncological results, functional outcomes and health-related quality-of-life in men who received a radical prostatectomy or external beam radiation therapy for localized prostate cancer: a study on long-term patient outcome with risk stratification.Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy.Surrogate end points: how well do they represent patient-relevant end points?Treatment of men with rising prostate-specific antigen levels following radical prostatectomy.Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling.Predictions for the future of kallikrein-related peptidases in molecular diagnostics.Phase II Clinical Trial of GM-CSF Treatment in Patients with Hormone-Refractory or Hormone-Naïve Adenocarcinoma of the Prostate.PSMA PET and Radionuclide Therapy in Prostate Cancer.L-dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer.SEOM clinical guidelines for treatment of prostate cancer.Factors determining biochemical recurrence in low-risk prostate cancer patients who underwent radical prostatectomy.Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results.Predictive and prognostic role of serum neopterin and tryptophan breakdown in prostate cancerQuantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression.Optimising preoperative risk stratification tools for prostate cancer using mpMRI.Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for prostate cancer 2017.Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy?
P2860
Q26747782-FC228CD3-91FD-40EF-91A3-AD671818A624Q33766462-EEDE7E99-C332-4C11-BDEF-75C0CADDC01DQ34039227-37D130D1-360A-4D43-B94A-6963C060C49BQ34437308-8BDB32AF-BC70-423C-B70F-4E81FB7796C3Q34997355-186FE132-AD2E-41F0-A859-ED19BFEE5B5DQ35070443-7CE1F419-2980-4291-AB47-544A70F10E1CQ35641782-E50756E5-F010-479C-92A4-E0A81074C23AQ35656240-FD9F93B3-B566-4AB0-8F91-F8D5F2AC2CEAQ35898174-3229E471-468E-4921-840C-EFE2B09F4891Q35937038-60E29861-C747-49AD-98AB-5A5B26AB9CD0Q36108417-91241D0E-43A3-46E3-81AA-0A38D2045F6CQ36173646-B9AFEADC-4B05-4B9C-B1DC-1A92851ACE64Q36432832-58C6C795-211F-4900-8D6A-9F5A6DBDEA48Q36516400-EE46B6CF-F8ED-428E-82BD-D499B793A598Q36547490-1657D3B6-4B61-4B7D-AA70-A70A912813BDQ36959130-55CEF964-89D6-40F2-8CB5-8334F0CF248AQ37074954-5A7B3A8F-D434-432E-9A0C-AB1D44604084Q37386391-BCD74E97-E83C-43D6-8463-0D1BC38A2F8AQ37755085-58F6D081-2C0C-425D-8CC9-D22063F779C7Q37821906-F04070C2-BDFC-4A0F-AA0D-49475BDF24D2Q37938241-49938379-566F-4F52-91B0-539061748186Q38220044-A6FA365F-6288-4428-BA17-37EC66D71FF1Q38260716-19D5D857-4874-4EB1-B758-1A2BB8B63043Q39003089-BF3F1C22-418F-4CBE-88DD-637A8C3358E1Q40034822-B5B5EC6F-212C-408C-BC17-6F8C7EED049DQ40043274-35C3C45E-166E-4C06-9538-4E34716A452DQ40586543-7DCE7A81-71A8-4B0A-8CC3-85AEA07E5AE1Q41898309-8CDF92BC-365F-47EA-B73A-1DD0A228422CQ42216809-A9CEB694-F663-4FF0-8793-FF508C226BDBQ45720150-E9D3AEE7-77EF-411E-A77C-68F5E56AA4C9Q49546387-C3E4D876-9394-43B8-85D1-BF9EFC2FEFF9Q55024078-9DE095B5-5357-4BC1-9130-16496238AD68Q57817247-EA1C4C71-E27E-453A-A60A-F19C6EFF77DD
P2860
Management of prostate-specific antigen relapse in prostate cancer: a European Consensus.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Management of prostate-specific antigen relapse in prostate cancer: a European Consensus.
@ast
Management of prostate-specific antigen relapse in prostate cancer: a European Consensus.
@en
type
label
Management of prostate-specific antigen relapse in prostate cancer: a European Consensus.
@ast
Management of prostate-specific antigen relapse in prostate cancer: a European Consensus.
@en
prefLabel
Management of prostate-specific antigen relapse in prostate cancer: a European Consensus.
@ast
Management of prostate-specific antigen relapse in prostate cancer: a European Consensus.
@en
P2093
P1476
Management of prostate-specific antigen relapse in prostate cancer: a European Consensus.
@en
P2093
Boccon-Gibod L
Hammerer P
Prayer-Galetti T
P304
P356
10.1111/J.1368-5031.2004.00184.X
P577
2004-04-01T00:00:00Z